Update on Board Investigation

AI SummaryClose X

SkinBioTherapeutics plc has announced an update on its board investigation, revealing that new information has led the board to seek the reversal of £0.77m in accrued royalty income from the audited FY25 revenues, potentially reducing FY25 revenue to £3.87m and restating adjusted EBITDA to a loss of £1.17m. The company maintains a robust cash balance of £2.92m as of February 13, 2026, and is initiating a search for an interim and then a permanent CEO. The board anticipates that the FY26 results will be significantly below current market expectations due to these adjustments.

Disclaimer*

UK 100

Latest directors dealings